Jonathan Barratt, PhD, FRCP

Panelists discuss potential biomarkers and clinical indicators that can aid in predicting disease outcomes for individual patients with IgA nephropathy.

Panelists discuss the immune system dysregulation underlying IgA nephropathy and highlight how this mechanism differs from those seen in other glomerular diseases.

Panelists discuss the progressive nature of immunoglobulin AIgA nephropathy (IgAN) and identify key factors that may accelerate its progression toward end-stage renal disease (ESRD).

Panelists discuss how IgA nephropathy presents in patients, often remaining asymptomatic until significant progression occurs, and explore the various subtypes that exhibit distinct clinical features.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on updates related to atrasentan.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on felzartamab.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, particularly data on long-term use of Nefecon.

In this segment, Barratt reflects on recent updates from the SPARTAN trial examining use of sparsentan as a first-line therapy in IgAN.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy.

Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, discuss the future of IgAN treatment, highlighting the BlyS/APRIL axis.

Drs Jonathan Barratt and Brad Rovin comment on clinical trial data regarding the use of povetacicept for the treatment of IgAN.

Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, review clinical trials for new and emerging treatments for IgAN, highlighting atacicept and telitacicept.

Nephrology experts explore the role of dual inhibition of BlyS and APRIL in the treatment of IgAN, and how this can impact disease pathogenesis.

Brad Rovin, MD, outlines the use of complement inhibitors as an alternative to systemic glucocorticoids for the treatment of IgAN.

Experts in nephrology focus on the need for an agent which inhibits the pathogenesis or interrupts disease progression of IgAN.

Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, provide an overview of the foundational therapies approved for treatment of IgAN and their functions.

Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, review the driving factors of disease progression of IgAN (immunoglobulin A nephropathy).

Gerald B. Appel, MD, discusses the changing treatment landscape of IgAN.

Anuja Java, MD, discusses the role of complement inhibitors in transplant patients with C3G.

Carla M. Nester, MD, MSA, FASN discusses recent clinical trials on complement inhibitors for C3G.

Carla M. Nester, MD, MSA, FASN discusses the current therapeutic area for C3G and what is on the horizon.

Anuja Java, MD, discusses barriers to perform kidney biopsies to diagnose immune mediated kidney diseases in community settings.

Sanjeev Sethi, MD, discusses clues in the pathology of kidney biopsies that could lead to a C3G diagnosis.

A panel of glomerular disease specialists discuss the importance of building centers of excellence with expertise on the pathology of C3G.

Sanjeev Sethi, MD, discusses the role of the diagnostic kidney biopsy in C3G.

Carla M. Nester, MD, MSA, FASN, discusses the approach to diagnostic testing in pediatric patients suspected of C3G.

Anuja Java, MD, discusses the diagnostic tests that could lead to a diagnosis of C3G.

Sanjeev Sethi, MD, and Gerald B. Appel, MD, discuss how the kidney biopsy can guide treatment and prognosis in IgAN.

Sanjeev Sethi, MD, discusses the role of the electro microscopy in IgAN.

Sanjeev Sethi, MD, discusses the role of the diagnostic kidney biopsy in IgAN.